Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Receives $9.00 Average PT from Analysts

Aclaris Therapeutics, Inc. (NASDAQ:ACRS) has been given a consensus recommendation of “Hold” by the six research firms that are currently covering the stock, Marketbeat reports. Six investment analysts have rated the stock with a hold rating. The average 12-month price target among analysts that have updated their coverage on the stock in the last year is $9.00.

ACRS has been the subject of a number of research reports. HC Wainwright reaffirmed a “neutral” rating on shares of Aclaris Therapeutics in a report on Tuesday, September 17th. StockNews.com upgraded shares of Aclaris Therapeutics from a “sell” rating to a “hold” rating in a research note on Thursday, July 25th.

Institutional Investors Weigh In On Aclaris Therapeutics

Several hedge funds have recently bought and sold shares of the stock. SG Americas Securities LLC increased its holdings in shares of Aclaris Therapeutics by 69.5% during the 1st quarter. SG Americas Securities LLC now owns 32,843 shares of the biotechnology company’s stock valued at $41,000 after purchasing an additional 13,461 shares in the last quarter. Trium Capital LLP grew its position in Aclaris Therapeutics by 1.1% during the third quarter. Trium Capital LLP now owns 1,912,990 shares of the biotechnology company’s stock valued at $2,200,000 after buying an additional 20,940 shares during the period. BNP Paribas Financial Markets increased its holdings in Aclaris Therapeutics by 10.9% in the first quarter. BNP Paribas Financial Markets now owns 241,101 shares of the biotechnology company’s stock valued at $299,000 after buying an additional 23,747 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. acquired a new position in shares of Aclaris Therapeutics in the first quarter worth about $39,000. Finally, Russell Investments Group Ltd. boosted its stake in shares of Aclaris Therapeutics by 5,265.1% during the 1st quarter. Russell Investments Group Ltd. now owns 62,772 shares of the biotechnology company’s stock worth $78,000 after acquiring an additional 61,602 shares in the last quarter. Hedge funds and other institutional investors own 98.34% of the company’s stock.

Aclaris Therapeutics Trading Up 15.5 %

Shares of Aclaris Therapeutics stock opened at $2.09 on Wednesday. Aclaris Therapeutics has a 12-month low of $0.59 and a 12-month high of $5.70. The firm’s 50 day simple moving average is $1.25 and its two-hundred day simple moving average is $1.22. The firm has a market capitalization of $149.12 million, a price-to-earnings ratio of -2.55 and a beta of 0.10.

Aclaris Therapeutics (NASDAQ:ACRS) last released its earnings results on Wednesday, August 7th. The biotechnology company reported ($0.15) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.19) by $0.04. The firm had revenue of $2.77 million for the quarter, compared to the consensus estimate of $1.74 million. Aclaris Therapeutics had a negative return on equity of 53.18% and a negative net margin of 183.28%. On average, sell-side analysts predict that Aclaris Therapeutics will post -0.65 EPS for the current fiscal year.

About Aclaris Therapeutics

Aclaris Therapeutics, Inc a clinical-stage biopharmaceutical company, engages in the development of novel drug candidates for immune-inflammatory diseases in the United States. The company operates through two segments, Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing therapies to address significant unmet needs for immuno-inflammatory diseases.